Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26043073 | 1.00 | ATM (0.50) | ATMCACNA1BCA1CA2ACHE | |
| SCHEMBL28602766 | 0.86 | SYK (0.47) | ATMSYKCNR2PPARACTSL | |
| SCHEMBL1310538 | 0.85 | NPSR1 (0.43) | CACNA1BPPARAPPARGCTSSMAPT | |
| SCHEMBL31563025 | 0.85 | ATM (0.61) | ATMCA1CA2ACHECNR2 | |
| SCHEMBL20821100 | 0.85 | NPSR1 (0.47) | CACNA1BPPARAKLK5PPARGCTSS | |
| SCHEMBL31563026 | 0.85 | NPSR1 (0.47) | CACNA1BPPARAKLK5PPARGCTSS | |
| SCHEMBL10100489 | 0.83 | ATM (0.51) | ATMCACNA1BCA1CA2ACHE | |
| SCHEMBL12292863 | 0.83 | ATM (0.54) | ATMCACNA1BCA1CA2ACHE | |
| SCHEMBL12293236 | 0.83 | ATM (0.54) | ATMCACNA1BCA1CA2ACHE | |
| SCHEMBL12292858 | 0.83 | ATM (0.56) | ATMCACNA1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976053-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | KEZAR LIFE SCIENCES, INC. (US) | 2024-05-07 | — | — | US | claimed |
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES, INC. | 2023-05-04 | — | — | US | claimed |
| WO-2025087220-A1 | METHOD FOR PREPARING (2S,3R)-2-SUBSTITUTED AMINO-3-HYDROXY-3-(4-METHOXYPHENYL)PROPIONATE | 科辉智药(深圳)新药研究中心有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-11976053-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | KEZAR LIFE SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4296257-A2 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR | Kezar Life Sciences (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3478669-B1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR | KEZAR LIFE SCIENCES (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3478669-B1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR | KEZAR LIFE SCIENCES (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11498907-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | KEZAR LIFE SCIENCES (US) | 2022-11-15 | — | — | US | disclosed |
| US-20200407334-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10781192-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | KEZAR LIFE SCIENCES (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190194155-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | KEZAR LIFE SCIENCES (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976053-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | PREP, PSMB2, PSME1 | ATM 3245/4885CACNA1B 2623/4885CA1 1987/4885 |
| US-20230135100-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | PREP, PSMB2, PSME1 | ATM 3294/4885CACNA1B 2575/4885CA1 1990/4885 |
| US-20200407334-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | PREP, PSMB2, PSME1 | ATM 3294/4885CACNA1B 2575/4885CA1 1990/4885 |
| US-10781192-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | PREP, PSMB2, PSME1 | ATM 3245/4885CACNA1B 2612/4885CA1 2009/4885 |
| US-20190194155-A1 | PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF | PREP, PSMB2, PSME1 | ATM 3245/4885CACNA1B 2612/4885CA1 2009/4885 |
| US-11498907-B2 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | PREP, PSMB2, PSME1 | ATM 3294/4885CACNA1B 2575/4885CA1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.